Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol + Alverine for Portal Hypertension in Cirrhosis
NCT06696248Phase 3Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of alverine in Portal Hypertension (PH), sponsored by Shanghai Changzheng Hospital. Primary endpoint: The 24-week response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
alverine
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT06696248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696248.